CD4 and cholangiocarcinoma: And it has been demonstrated that PD-1 expression increased in CCA patients with CD4+ and CD8+ tumor‐infiltrating lymphocytes (TILs), and the level of effector cytokines in TILs was positively correlated with nivolumab (47).